ABCL (AbCellera Biologics) Tax Rate %: 12.86% (As of Mar. 2026)


ABCL AbCellera Biologics Inc ABCL
59 GF Score
Price $7.60
GF Value $5.53
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is AbCellera Biologics Tax Rate %?

AbCellera Biologics ABCL +0.07% 59 Tax Rate % is 12.86% as of Mar. 2026. GuruFocus rates ABCL with a GF Score™ of 59/100 and a GF Value™ of $5.53 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. AbCellera Biologics's Tax Expense for the three months ended in Mar. 2026 was $-6.37 Mil. AbCellera Biologics's Pre-Tax Income for the three months ended in Mar. 2026 was $-49.54 Mil. Therefore, AbCellera Biologics's Tax Rate % for the quarter that ended in Mar. 2026 was 12.86%.

AbCellera Biologics Tax Rate % Related Terms

AbCellera Biologics Tax Rate % Historical Data

* Premium members only.

The historical data trend for AbCellera Biologics's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbCellera Biologics Tax Rate % Chart

AbCellera Biologics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Rate %
Get a 7-Day Free Trial 29.97 33.70 15.88 18.73 17.56

AbCellera Biologics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.90 4.45 16.94 54.13 12.86
ABCL
59GF Score
AbCellera Biologics Inc ABCL
Tax Rate % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbCellera Biologics Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

AbCellera Biologics's Tax Rate % for the fiscal year that ended in Dec. 2025 is calculated as

Tax Rate %=Tax Expense (A: Dec. 2025 )/Pre-Tax Income (A: Dec. 2025 )
=-31.183/-177.595
=17.56 %

AbCellera Biologics's Tax Rate % for the quarter that ended in Mar. 2026 is calculated as

Tax Rate %=Tax Expense (Q: Mar. 2026 )/Pre-Tax Income (Q: Mar. 2026 )
=-6.372/-49.537
=12.86 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Rate % →
What does a Tax Rate % of 12.86% mean?
AbCellera Biologics (ABCL) has a Tax Rate % of 12.86% as of Mar. 2026.
Is AbCellera Biologics' Tax Rate % too high?
AbCellera Biologics' current Tax Rate % is 12.86%. Overall, AbCellera Biologics has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Tax Rate % compare to AGIO and KOD?
AbCellera Biologics' Tax Rate % of 12.86% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Rate % for a Biotechnology company?
A good Tax Rate % depends on the Biotechnology industry context. However, Tax Rate % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Rate % mean?
A high Tax Rate % can signal that a stock is expensive relative to its fundamentals. AbCellera Biologics's current Tax Rate % is 12.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.53, compared to a current price of $7.60 — trading 37.4% above its estimated fair value. The current Tax Rate % is 12.86%. AbCellera Biologics' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Rate % calculated?
Tax Rate % is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Tax Rate % is 12.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbCellera Biologics (ABCL) Overvalued in 2026?

Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued. The current stock price of $7.60 is trading 37.4% above its estimated GF Value™ of $5.53. GuruFocus considers AbCellera Biologics to be Significantly Overvalued.

Key valuation signals for ABCL:

  • Tax Rate %: 12.86%
  • GF Value™: $5.53 vs. price of $7.60 (37.4% above fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbCellera Biologics Business Description

Other Exchanges 8QQ:Germany
Address 150 W 4th Avenue, Vancouver, BC, CAN, V5Y 1G6
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
59GF Score

Get the complete analysis for ABCL

Tax Rate % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.60
Price
$5.53
GF Value